From All Angles

Panelists discuss how effective patient education, coordinated multidisciplinary care, strong caregiver advocacy, and proactive management of talquetamab’s unique adverse effects through standardized protocols and comprehensive handouts enable patients with relapsed/refractory multiple myeloma to successfully navigate bispecific antibody therapy while maintaining quality of life.

Panelists emphasize a comprehensive, patient-centered approach to multiple myeloma care that integrates multidisciplinary expertise, personalized education, collaborative decision-making, innovative treatments, and strong support systems to improve outcomes and quality of life for patients and caregivers.